China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Get Free Report) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 721,044 shares, a growth of 999.1% from the September 30th total of 65,603 shares. Based on an average daily volume of 52,120,891 shares, the short-interest ratio is currently 0.0 days. Currently, 157.1% of the shares of the stock are short sold.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on SXTC shares. Wall Street Zen upgraded shares of China SXT Pharmaceuticals to a “sell” rating in a research note on Saturday, August 22nd. Weiss Ratings upgraded shares of China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, October 21st. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, China SXT Pharmaceuticals currently has an average rating of “Sell”.
Read Our Latest Report on SXTC
China SXT Pharmaceuticals Price Performance
Shares of SXTC stock traded down $0.56 on Monday, hitting $3.54. 188,145 shares of the company’s stock were exchanged, compared to its average volume of 64,702,860. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.94 and a quick ratio of 7.76. China SXT Pharmaceuticals has a 12 month low of $3.37 and a 12 month high of $8,375,880.00. The company has a 50 day moving average of $209.45 and a 200 day moving average of $37,799.87.
About China SXT Pharmaceuticals
China SXT Pharmaceuticals, Inc (NASDAQ: SXTC) is a pharmaceutical company based in Taizhou, Jiangsu Province, China. The company develops, manufactures and sells traditional Chinese medicine products, serving customers primarily in the Chinese market.
Its product portfolio includes prescription and over-the-counter traditional Chinese medicines, as well as health-related products and dietary supplements. The company’s operations encompass the preparation of herbal ingredients and the production, marketing and distribution of finished traditional Chinese medicine products.
China SXT Pharmaceuticals was established in 2005 and completed its initial public offering on the Nasdaq Capital Market in 2019.
Further Reading
- Five stocks we like better than China SXT Pharmaceuticals
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for China SXT Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China SXT Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
